Tirzepatide
Dual GLP-1 and GIP receptor agonist.
Tirzepatide
Compounded tirzepatide · dose personalized to you
From $199/mo
Activates both GLP-1 and GIP receptors — the two gut hormones that signal appetite and satiety. In clinical trials the active medication reduced body weight by up to 22%. A licensed provider reviews your intake, sets your titration, and adjusts it as your body changes.
- No insurance required
- Licensed U.S. providers
- Pharmacies we name
- Founded by patients
- Fast, discreet shipping
- Unlimited follow-up with your clinician
$0 Membership fees
See If You Qualify Not sure? See all plans and pricing You choose your plan during the medical intake. Your per-month price never climbs with your dose.
How it works
Built to keep signalling long after a meal.
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Receptors sit in the brain, gut and pancreas, where activation supports appetite regulation and metabolic function.
Activates GLP-1 and GIP receptors
Tirzepatide is a dual agonist: it acts on both of the gut-hormone receptors that signal fullness, rather than GLP-1 alone.
Signals satiety for days, not minutes
The GLP-1 your gut makes is broken down by the DPP-4 enzyme within minutes. A receptor agonist is engineered to keep signalling long enough for once-weekly dosing.
Slows gastric emptying
Food leaves the stomach more gradually, which extends the feeling of fullness after a meal and is also why dose titration matters for tolerability.
The evidence
What the trials actually measured.
The largest average reduction of any trial in its class.
SURMOUNT-1 randomised adults with obesity or overweight to weekly tirzepatide or placebo for 72 weeks. Results are for the active medication studied in the trial, not for REMEVi patients — individual results vary.
72 weeks Trial duration
up to 22% Mean body-weight reduction at the highest dose
Source: Jastreboff AM et al. "Tirzepatide Once Weekly for the Treatment of Obesity" (SURMOUNT-1), New England Journal of Medicine, 2022.
Natural GLP-1 lasts minutes. A receptor agonist lasts days.
Every time you eat, your gut releases GLP-1, which signals fullness and slows digestion — and an enzyme called DPP-4 destroys it almost immediately. Receptor agonists are built to resist that breakdown, which is what makes a single weekly injection possible instead of dosing after every meal.
1–2 min How long the GLP-1 your gut produces stays active
up to ~5,000× Longer-lasting than the natural hormone across the class (2.5 hours to ~7 days)
Source: Nauck MA, Meier JJ, "Are All GLP-1 Agonists Equal in the Treatment of Type 2 Diabetes?", European Journal of Endocrinology, 2019; Gentilella R et al., Diabetes/Metabolism Research and Reviews, 2019.
The dose is stepped up deliberately, not started high.
Your provider begins low and increases every four weeks, because most gastrointestinal side effects track with how fast the dose rises rather than the final dose itself. Personalised titration is the specific clinical reason a compounded preparation may be appropriate.
4 weeks Between dose steps
Unlimited Provider messages while titrating
Source: REMEVi clinical protocol; your provider adjusts the schedule to your response and tolerability.
Stopping is what undoes it.
STEP-4 is the trial most programs never mention, and the one that should shape how you budget. Patients who continued treatment held their loss; patients switched to placebo regained. That is why REMEVi prices for the long run rather than discounting a first month you are then meant to grow out of.
+6.9% Regained after withdrawal
n = 803 Randomized · continued vs withdrawn
Source: Rubino D, Abrahamsson N, Davies M, et al. Effect of Continued Weekly Semaglutide vs Placebo on Weight Maintenance. JAMA 2021;325:1414–1425. doi:10.1001/jama.2021.3224
Trial figures describe the active medication studied, not compounded preparations or REMEVi outcomes, and are not a guarantee of individual results. Compounded medications are not FDA-approved drug products.
How REMEVi works
Reviewed within 24 hours, shipped in one to three days.
See If You Qualify
A licensed provider decides whether treatment is appropriate — nobody is prescribed automatically.
-
Step 1Medical intake
A guided set of questions covering your history, current medications, and goals.
About 5 minutes -
Step 2Clinician review
A licensed provider in your state reviews your intake and prescribes only if it is clinically appropriate.
Within 24 hours -
Step 3Pharmacy and shipping
A named, state-licensed pharmacy fills your prescription and ships it cold-chain in discreet packaging.
Ships 1–3 days after approval -
Step 4Follow-up, in your language
Message your care team as often as you need for dose adjustments and side-effect support, in English or Spanish.
Unlimited, every month
Some states require a live audio or video consultation before a prescription can be approved, which can add a day or two.
Explore other treatments
Semaglutide
The most-studied GLP-1 for weight management.
View treatment
Oral semaglutide
Daily tablet for needle-free dosing.
View treatment
NAD+ injections
Replenish NAD+, which declines with age.
View treatment
Sermorelin
Stimulates the pituitary's own growth hormone.
View treatment
Glutathione
Antioxidant support against oxidative stress.
View treatmentTreatment plan
Tirzepatide dosing protocol
Provider-supervised dose escalation every 4 weeks to maximize results and minimize side effects.
Dose escalation
Weeks 1–4
2.5 mg
Starter dose weekly
Weeks 5–8
5 mg
First therapeutic dose
Weeks 9–12
7.5 mg
Increased every 4 weeks
Weeks 13–24
10–15 mg
Titrate to maintenance
Delivery & support
Injection method
Subcutaneous (under the skin)
Frequency
Once per week
Provider check-ins
Monthly dose adjustments
Timeline
Full 24-week program
What to expect
Tirzepatide results timeline
Weight loss milestones and what patients typically experience at each phase.
Weeks 1–4
Appetite suppression
Noticeable decrease in hunger and food cravings begins.
Weeks 5–12
5–10% loss
Body weight reduction of 5–10% is common at this phase.
Weeks 13–24
Up to 15–22%
Total body weight loss in clinical trials (SURMOUNT-1).
Ongoing
Maintenance
Maintenance dosing available to preserve results long-term.
Results vary based on adherence, diet, exercise, and individual metabolism. Your REMEVi licensed provider will monitor your progress and adjust dosing as needed.
Why REMEVi Health
The clinical standard, personalized to your goals.
Licensed U.S. providers
A clinician licensed in your state reviews every intake and sets your titration. No wait lists, no insurance required.
One flat price
Your per-month price never climbs with your dose. No membership fee, no lab fee, no dose upcharge.
Named pharmacies
We publish which state-licensed compounding pharmacies fill our prescriptions, and the name appears on your vial label.
Bilingual care
Real people on WhatsApp in English and Spanish — the reason REMEVi exists, not an add-on service tier.
The REMEVi Flat-Dose Guarantee
Your price never rises with your dose. Ever.
Most programs charge more as your dose increases. At REMEVi, your price stays flat at every dose — with no separate membership fee on top of the medication price.
Compare with Semaglutide What compounded tirzepatide costs Compounded Zepbound alternative
THE 4 QUESTIONS EVERYONE ASKS
Named out loud, answered in full.
REMEVi's semaglutide is compounded by a 503B outsourcing facility registered with the FDA — the same regulatory tier hospitals use. Compounded medications are not FDA-approved finished drug products; they are prepared under the 503A or 503B framework to USP <797> sterility standards and prescribed by a licensed provider in your state who will review the risks, benefits, and considerations with you.
Facility tier
FDA-registered 503B
Sterility standard
USP <797>
Active ingredient
Semaglutide
Provider network
All 50 states + DC
FAQ
Tirzepatide questions answered
Tirzepatide is a dual GIP/GLP-1 receptor agonist medication approved for weight management. It works by reducing appetite and improving blood sugar regulation.
REMEVi prescribes compounded tirzepatide, which is not the same as, and is not a generic version of, Mounjaro® or Zepbound® (FDA-approved finished drug products manufactured by Eli Lilly). Compounded tirzepatide is a non-FDA-approved preparation prepared by a state-licensed compounding pharmacy under an individual prescription from a licensed US provider. Compounded preparations have not been clinically studied as finished products. Your licensed provider will review risks, benefits, and considerations with you before prescribing.
It is a flat $319/month on the monthly plan, $249/mo on the 12-week plan, or as low as $199/mo on the 52-week plan. All plans are all-inclusive — no hidden fees.
Clinical trials (SURMOUNT-1) showed tirzepatide at the highest dose produced up to 22% body weight loss, generally outperforming semaglutide trials. Individual results vary.
Most patients notice appetite changes in the first 2–4 weeks. Meaningful weight loss typically becomes visible by weeks 8–12.
Yes. Your REMEVi licensed provider can evaluate a transition during your consultation.
Disclaimer: This page is for educational purposes and is not medical advice, diagnosis or treatment. Compounded tirzepatide is not FDA-approved and is not a generic version of Mounjaro® or Zepbound®. Your provider prescribes a compounded preparation only when they determine it offers a meaningful clinical difference for you — such as personalized dose titration. Eligibility and prescriptions are determined solely by licensed medical providers based on clinical appropriateness; not everyone will qualify. Trial results describe the active medication studied, not REMEVi outcomes. Individual results vary.
The GLP-1 Guide · Free
Not ready to start today? Take the guide with you.
What GLP-1 is, how it works, what to expect, and nutrition tips — in English and Spanish. Free, straight to your inbox.
No spam. Unsubscribe anytime.